| Literature DB >> 28215051 |
Heike Wanka1, Philipp Lutze1, Doreen Staar1, Barbara Peters1, Anica Morch1, Lukas Vogel1, Ravi Kumar Chilukoti2, Georg Homuth2, Jaroslaw Sczodrok1, Inga Bäumgen1, Jörg Peters1.
Abstract
The (pro)renin receptor [(P)RR, ATP6AP2] is a multifunctional transmembrane protein that activates local renin-angiotensin systems, but also interacts with Wnt pathways and vacuolar H+ -ATPase (V-ATPase) during organogenesis. The aim of this study was to characterize the role of ATP6AP2 in the cell cycle in more detail. ATP6AP2 down-regulation by siRNA in renal As4.1 cells resulted in a reduction in the rate of proliferation and a G0/G1 phase cell cycle arrest. We identified a number of novel target genes downstream of ATP6AP2 knock-down that were related to the primary cilium (Bbs-1, Bbs-3, Bbs-7, Rabl5, Ttc26, Mks-11, Mks-5, Mks-2, Tctn2, Nme7) and the cell cycle (Pierce1, Clock, Ppif). Accordingly, the number of cells expressing the primary cilium was markedly increased. We found no indication that these effects were dependent of V-ATPase activity, as ATP6AP2 knock-down did not affect lysosomal pH and bafilomycin A neither influenced the ciliary expression pattern nor the percentage of ciliated cells. Furthermore, ATP6AP2 appears to be essential for mitosis. ATP6AP2 translocated from the endoplasmatic reticulum to mitotic spindle poles (pro-, meta- and anaphase) and the central spindle bundle (telophase) and ATP6AP2 knock-down results in markedly deformed spindles. We conclude that ATP6AP2 is necessary for cell division, cell cycle progression and mitosis. ATP6AP2 also inhibits ciliogenesis, thus promoting proliferation and preventing differentiation.Entities:
Keywords: (P)RR/ATP6AP2; V-ATPase; cell cycle; ciliogenesis; proliferation
Mesh:
Substances:
Year: 2017 PMID: 28215051 PMCID: PMC5487920 DOI: 10.1111/jcmm.13069
Source DB: PubMed Journal: J Cell Mol Med ISSN: 1582-1838 Impact factor: 5.310
Figure 1ATP6AP2 expression is efficiently down‐regulated by siRNA interference. Efficacy of ATP6AP2 knock‐down using 40 nM siRNA was checked time dependently by (A) qRT‐PCR normalized to the housekeeping gene YWHAZ and the scramble control [ATP6AP2 (2−∆∆CT)] (n = 9) as well as by (B and C) Western blotting normalized to total protein content (n = 5). (B) Representative Western blots depict the protein bands at 37 and 28 kD corresponding to the full‐length and the soluble ATP6AP2. (C and D) Quantification of protein bands at 37 and 28 kD related to total protein. ***P < 0.001 versus controls.
Figure 2Cell death induced by ATP6AP2 knock‐down and V‐ATPase inhibition related to acidification of lysosomal compartments. (A) Viability of the cells as checked by propidium iodide labelling (n = 14). (B and C) Percentage of apoptotic annexin V‐positive cells (n = 9) and caspase‐positive cells (n = 8) determined by flow cytometry. (D) Representative FACS analyses of LysoTracker‐positive cells pretreated for 24 hrs by scramble siRNA, by siRNA to ATP6AP2 or by bafilomycin (1 μmol/l). (E) Quantitative FLI data of LysoTracker‐positive cells (n = 6). ***P < 0.001; **P < 0.01 and *P < 0.05 versus controls.
Transcripts identified downstream of ATP6AP2/(P)RR 24 hrs after transfection
| Sequence ID | Gene symbol | Protein name |
| Fold change | Chrom | Localization | Ref. |
|---|---|---|---|---|---|---|---|
| 1124131 |
| ATPase, H+ transporting lysosomal accessory protein 2 | 0.030 | −2.57 | X | Membrane, ER | |
| Primary cilia/flagella | |||||||
| 1129411 |
| RAB, member of RAS oncogene family‐like 5 | 0.012 | 2.13 | 5 | Ift complex B |
|
| 1102442 |
| Tetratricopeptide repeat domain 26 | 0.003 | 1.79 | 6 | Ift complex B |
|
| 1130399 |
| RIKEN cDNA 4932417I16 gene | 0.007 | 1.91 | 8 | TZ |
|
| 1136082 |
| Rpgrip1‐like | 0.041 | 1.78 | 8 | TZ, basal body |
|
| 1123486 |
| Tectonic family member 2 | 0.029 | 1.78 | 5 | TZ |
|
| 1105543 |
| Transmembrane protein 216 | 0.046 | 1.51 | 19 | TZ, basal body |
|
| 1120695 |
| Bardet–Biedl syndrome 1 (human) | 0.017 | 1.70 | 19 | BBSome |
|
| 1130375 |
| Bardet–Biedl syndrome 7 (human) | 0.027 | 1.52 | 3 | BBSome, centrosome |
|
| 1135586 |
| ADP‐ribosylation factor‐like 6 | 0.026 | 1.55 | 16 | BBSome, cytosol |
|
| 1112414 |
| Non‐metastatic cells 7, protein expressed in (nucleoside‐diphosphate kinase) | 0.038 | 1.65 | 1 | γ‐tubulin ring Complex, centrosome |
|
| Cell cycle | |||||||
| 1117889 |
| RIKEN cDNA 1700007K13 gene | 0,043 | 2.20 | 2 | Unknown |
|
| 1110632 |
| Peptidylprolyl isomerase F (cyclophilin F, D) | 0.032 | 1.57 | 14 | Mitochondria, cytosol |
|
| 1129925 |
| Circadian locomoter output cycles kaput | 0.029 | −1.67 | 5 | Cytosol, nucleus |
|
| Cell migration/cytoskeleton | |||||||
| 1105470 |
| Slit homologue 3 (Drosophila) | 0.009 | −1.66 | 11 | Secretion |
|
| 1136195 |
| RIKEN cDNA A230083H22 gene | 0.048 | −1.65 | 19 | Cytosol, endosomes, microtubuli |
|
| Secretory pathway/traffick | |||||||
| 1124988 |
| ATP‐binding cassette, subfamily B (MDR/TAP), member 6 | 0.020 | 1.57 | 1 | ER, endo‐, exosomes |
|
| 1108606 |
| Acyl‐CoA synthetase long‐chain family member 4 | 0.007 | −1.61 | X | ER, lysosomes |
|
| 1133354 |
| Leucine‐rich repeat containing 8 family, member B | 0.023 | −1.78 | 10 | Membrane, VRAC |
|
| 1103969 |
| Lethal, Chr 7, Rinchik 6 | 0.042 | −1.95 | 7 | ER, cytosol, nucleus |
|
| Extracellular matrix | |||||||
| 1130315 |
| Matrix metallopeptidase 19 | 0.040 | −1.75 | 10 | Secretion |
|
| Transcription/translation | |||||||
| 1136275 |
| TAR (HIV) RNA‐binding protein 2 | 0.035 | 1.55 | 15 | Cytosol, nucleus |
|
| 1133367 |
| DALR anticodon binding domain containing 3 | 0.045 | 1.65 | 9 | Cytosol, nucleus |
|
| 1120276 |
| FK506‐binding protein 3 | 0.013 | −1.84 | 12 | ER, cytosol, nucleus |
|
| Apoptosis | |||||||
| 1116780 |
| PREDICTED: Mus musculus similar to ornithine decarboxylase (LOC100045562), misc RNA. | 0.034 | 1.67 | 7 | Cytosol; ER, Golgi |
|
| 1119394 |
| Ubiquitin‐conjugating enzyme E2 variant 2 | 0.048 | −1.54 | 16 | Cytosol |
|
| Wnt/ß‐Catenin pathway | |||||||
| 1122967 |
| Cytochrome P450, family 1, subfamily a, polypeptide 1 | 0.025 | 2.19 | 9 | Cytosol, microsomes |
|
| 1126392 |
| Fin bud initiation factor homologue (zebrafish) | 0.046 | −2.49 | 2 | ER, Golgi, secretion |
|
| Unknown protein/function | |||||||
| 1109622 |
| Expressed sequence AI429214 | 0.042 | 2.01 | 8 | ||
| 1131132 | 0.048 | 1.72 | |||||
| 1110402 | 0.015 | −1.50 | |||||
The sequence ID, primary sequence name (gene symbol), anova statistic, fold changes and the chromosomal and protein localization are listed for each corresponding protein linked to a signalling pathway. Data represent three experiments with statistical analysis according to anova post hoc test.
Indicates alternative name.
Chrom: Chromosome; Ref: References; Bbs: Bardet–Biedl Syndrome; Mks: Meckel–Gruber Syndrome; Ift: intraflagellar transport; TZ: transition zone; ER: endoplasmatic reticulum; VRAC: volume‐regulated anion channel.
Figure 3ATP6AP2 down‐regulation changes expression pattern of transcripts associated with primary cilia and cell cycle. PCR array data of As4.1 cells pretreated with scramble siRNA or with siRNA to ATP6AP2 (each 40 nmol) for 24 hrs. Expression data (n = 6) were normalized to the housekeeping gene YWHAZ and to the scramble control (2−∆∆CT). ***P < 0.001; **P < 0.01; *P < 0.05 versus scramble control.
Transcripts regulated by both siRNA‐mediated ATP6AP2 knock‐down and V‐ATPase inhibition
| Sequence ID | Gene symbol | Protein name | Fold change | |
|---|---|---|---|---|
| siRNA | Bafi | |||
| 1124131 |
| ATPase, H+ transporting, lysosomal accessory protein 2 | −2.57 | 2.51 |
| 1134827 |
| Actin, α 2, smooth muscle, aorta | 2.58 | −4.68 |
| 1115329 |
| Alkaline phosphatase, liver/bone/kidney | 1.51 | −3.16 |
| 1123891 |
| ATPase, Na+/K+ transporting, β 1 polypeptide | 1.69 | −2.34 |
| 1123050 |
| Bone morphogenetic protein 4 | 2.06 | −2.60 |
| 1122659 |
| Carbonic anhydrase 9 | −1.77 | 3.22 |
| 1131781 |
| Caveolin 1, caveolae protein | 1.68 | −4.83 |
| 1134774 |
| Chemokine (C‐C motif) ligand 2 | 2.20 | −4.16 |
| 1129352 |
| ChaC, cation transport regulator‐like 1 ( | 2.47 | 1.99 |
| 1125858 |
| Dipeptidylpeptidase 7 | 1.78 | 2.74 |
| 1132231 |
| Glutamyl aminopeptidase | −1.68 | −3.47 |
| 1112069 |
| c‐fos‐induced growth factor | 2.07 | −1.95 |
| 1109935 |
| Growth arrest and DNA damage‐inducible 45 α | −3.40 | 2.53 |
| 1134045 |
| Heat shock protein 1A | 1.86 | −2.23 |
| 1109017 |
| Heat shock protein 1B | 1.54 | −2.43 |
| 1135433 |
| Histone cluster 1, H1a | −1.38 | −1.95 |
| 1119748 |
| Immunity‐related GTPase family M | 1.93 | −2.18 |
| 1133764 |
| Insulin‐like growth factor‐binding protein 4 | −1.54 | −2.80 |
| 1108676 |
| Leucine‐rich repeat LGI family, member 2 | −1.82 | −1.97 |
| 1105408 |
| Lymphocyte antigen 6 complex, locus D | −1.73 | −4.51 |
| 1120944 |
| Mesoderm specific transcript | 1.91 | −7.92 |
| 1112577 |
| Metallothionein 2 | 3.95 | 5.53 |
| 1104559 |
| Nuclear factor of kappa light polypeptide gene enhancer in B‐cells inhibitor, α | 1.62 | −2.30 |
| 1117142 |
| Purinergic receptor P2X, ligand‐gated ion channel, 3 | −5.34 | −2.86 |
| 1114155 |
| Peptidyl arginine deiminase, type II | −2.00 | −2.87 |
| 1118509 |
| Peptidase inhibitor 15 | 2.09 | −4.63 |
| 1130399 |
| RIKEN cDNA 4932417I16 gene | 1.91 | 2.16 |
| 1111109 |
| RIKEN cDNA B430001I08 gene | 1.53 | −2.77 |
| 1127478 |
| S100 calcium‐binding protein G | 1.74 | −2.60 |
| 1105372 |
| TAP‐binding protein | 1.55 | 1.86 |
| 1110002 |
| Thrombospondin 2 | −1.76 | −3.41 |
| 1122671 |
| Tumour necrosis factor (ligand) superfamily, member 15 | −2.10 | −7.79 |
| 1112165 |
| Tripeptidyl peptidase I | 1.52 | 2.03 |
| 1119180 |
| V‐set domain containing T‐cell activation inhibitor 1 | 3.39 | −2.28 |
The sequence ID, primary sequence name (gene symbol) and fold changes are listed for each corresponding protein. Data represent one and three experiments, respectively, with statistical analyses according to t‐test and a minimum of 1.5‐fold changes.
Figure 4ATP6AP2 knock‐down enhances the expression of the primary cilium. (A) Representative fluorescence microscopic images of scramble controls (upper panel), ATP6AP2‐depleted cells (central panel) and bafilomycin‐treated cells (lower panel). Primary cilia (red) were probed with the anti‐ac‐α‐tubulin antibody. 4′,6′‐Diamidino‐2‐phenylindole (DAPI, blue) was used for labelling the cell nucleus. Bars represent an size of 50 and 10 μm. (B) Percentage of cells carrying a primary cilium n = 4; ***P < 0.001 versus control groups. (C and D) Correlation between the number of nuclei per field of vision and percentage of ciliated cells after ATP6AP2 knock‐down or bafilomycin treatment (data from n = 3 independent experiments).
Figure 5ATP6AP2 knock‐down and V‐ATPase inhibition cause restriction of proliferation and cell cycle arrest at different phases. (A and C) Representative cell cycle analyses of scramble controls, of ATP6AP2‐depleted cells 24 hrs after transfection and of bafilomycin‐treated cells. (B and D) Proportion of cells associated with different cell cycle phases (n = 8). (E) Proliferation rate as detected by the BrdU incorporation (n = 8). ***P < 0.001; **P < 0.01 and *P < 0.05 versus corresponding controls.
Figure 6Localization of ATP6AP2 during different cell cycle phases. Representative fluorescence microscopic images of untreated As4.1 cells during different phases of the cell cycle (A: G0/G1 phase, D: G2 phase, E: prophase, F: anaphase and G: telophase) or of ATP6AP2‐depleted cells (H) and bafilomycin‐treated cells (I) during mitosis. Anti‐PDI antibody (green) was used to mark the ER. Anti‐acetylated α‐tubulin antibody (red) was used for labelling of microtubules (mitotic spindle, midbody). ATP6AP2 distribution was detected with the anti‐ATP6AP2 antibody as indicated. Nuclei were labelled using DAPI (blue). Bars represent an size of 10 μm. (B and C): Representative Western blots showing the subcellular localization of ATP6AP2 in membrane and soluble fractions (B) as well as in different organelle fractions (C) verified by antibodies to GAPDH (cytosolic marker), AIF (mitochondrial marker) and CREB (nuclear marker).